Georgina Cornish

Georgina Cornish

Company: AstraZeneca

Job title: Associate Principle Scientist, Cell Therapy Safety


Georgina is the Associate Principle Research Scientist in the Cell Therapy Safety team at AstraZeneca overseeing in vivo toxicity models for the preclinical safety assessment of the CAR-T cell portfolio.

Prior to joining AstraZeneca, Georgina took an industrial placement which she co-ordinated and ran large scale CAR T-cell efficacy studies in immunocompromised mice carrying solid tumour xenografts.

Georgina has spent over 15 years studying immunity in health and disease, starting from the biochemical building blocks that translate environmental cues into immune cell function by utilising models of complex disease. During her PhD study in the early 2000’s, Georgina’s research focus was on describing a novel cytokine driven regulation of CD8+ T-cell metabolism pivotal to memory T cell differentiation and migration. In subsequent postdoctoral years, she focused on the immuno-modulatory effects of specialised tissue microenvironments in the context of autoimmune inflammation, transplantation and the generation, maintenance and survival of effector T-cells in vivo.



Roundtable Discussion: What Preclinical Models Provide a Platform to Assess Immunotherapy Toxicology? 10:40 am

Take advantage of this interactive session to join our expert speakers in the roundtable to ask your burning questions, share your recent preclinical success and hear how your peers have tackle similar problems to get inspirations!Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.